Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00330239
Status:
COMPLETED
Last Update Posted:
2007-10-03
First Post:
2006-05-25
Brief Title:
Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence
Sponsor:
Medical University of South Carolina
Organization:
Medical University of South Carolina
Study Overview
Official Title:
Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence
Status:
COMPLETED
Status Verified Date:
2007-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Pharmacotherapy has demonstrated efficacy in a number of controlled trials in the treatment of PTSD The selective serotonin reuptake inhibitors have proven particularly useful in treating this disorder Currently there are two selective serotonin reuptake inhibitors Zoloft and Paxil that have been FDA approved for treating PTSD Coincidentally this same class of medications has also been shown to have efficacy in some trials in decreasing alcohol consumption in heavy drinkers The goal of the proposed study is to preliminarily investigate the efficacy of Paxil paroxetine in decreasing symptoms of PTSD as well as decreasing substance use in individuals with concurrent substance dependence and PTSD The type of paroxetine used in this trial will be Paxil CR which is a sustained release formulation of paroxetine which has fewer side effects and greater tolerability This is a particularly important issue in substance using populations because medication compliance is generally poor
Two specific hypotheses will be tested 1 Individuals who receive Paxil CR will have a greater improvement in their PTSD symptoms based on CAPS-2 and CGI than those who receive placebo 2 Individuals who receive Paxil CR will have greater improvement in their substance use outcomes based on UDS and TLFB than will those who receive placebo
Two specific hypotheses will be tested 1 Individuals who receive Paxil CR will have a greater improvement in their PTSD symptoms based on CAPS-2 and CGI than those who receive placebo 2 Individuals who receive Paxil CR will have greater improvement in their substance use outcomes based on UDS and TLFB than will those who receive placebo
Detailed Description:
Participants who meet all inclusion and no exclusion criteria will be randomized with a 11 ratio to receive either Paxil CR or placebo for 12 weeks Medication will be initiated at 125mgday and will be increased weekly as tolerated to a maximum dose of 50mgday Participants will be seen weekly and will be assessed for side effects substance use since last visit urine drug screen breathalyzer readings vital signs and symptoms of PTSD TOP-8at each visit The Davidson Trauma Scale will be completed every two weeks and the CAPS-2 and MADRS will be completed monthly Those who complete the first 12 weeks of double-blind study medication will be eligible to receive open label medication for an additional 12 weeks Medication will be initiated at 125mg and increased every 3 days as tolerated to the terminal dose in the double-blind phase then adjusted as needed Participants will come in for assessments every two weeks of the open-label phase Blood will be drawn for blood chemistries and hematology at screening and weeks 12 and 24 Urine pregnancy tests will be performed for women of childbearing potential at baseline and again at weeks 4 12 and 24
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None